MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors.

迈阿密，2024年7月8日（环球通讯社）--Longeveron Inc.（纳斯达克：LGVN），一家临床阶段再生医学生物技术公司，开发针对威胁生命和慢性衰老相关疾病的细胞疗法，今天宣布，马萨诸塞州布里格姆将军基因与细胞疗法研究所所长罗杰·哈贾尔医学博士当选为Longeveron董事会成员。

Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the Gene and Cell Therapy Institute.

哈贾尔博士是一位国际公认的科学家，他的心脏基因治疗发现激发了心力衰竭的临床试验，目前世界各地的研究人员正在使用其心脏定向基因转移的方法，并被任命为基因和细胞治疗研究所的首任主任。

Dr. Hajjar was elected at the Company’s recent Annual Meeting of Stockholders..

哈贾尔博士在公司最近的年度股东大会上当选。。

“I am delighted to welcome Roger, and his tremendous experience as a scientist, academic, and operational executive, to the Board of Directors,” said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. “His thought leadership in gene and cell therapy will bring significant value to Longeveron as we continue to advance Lomecel-B™, our proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications.

Longeveron联合创始人、首席科学官兼董事会主席约书亚·黑尔（JoshuaHare）表示：“我很高兴欢迎罗杰（Roger）加入董事会，以及他作为科学家、学术界和运营管理者的丰富经验。”。。

I look forward to collaborating with him to advance these important therapeutic development programs.”.

我期待着与他合作，推进这些重要的治疗发展计划。”。

“I am excited to join the Longeveron Board at this important time, both for the Company and in the history of gene therapy,” said Dr. Hajjar. “Gene and cell therapy is revolutionizing patient care with the potential to cure diseases or halt their progression. The Lomecel-B™ data generated to date in HLHS and Alzheimer’s disease support broad potential for this novel cellular therapy as a regenerative medical therapy across multiple indications and position the Company to potentially profoundly impact affected patients’ lives for the better.”.

。“基因和细胞疗法正在彻底改变患者护理，有可能治愈疾病或阻止疾病进展。迄今为止，在HLHS和阿尔茨海默氏病中产生的Lomecel-B™数据支持这种新型细胞疗法作为跨越多种适应症的再生医学疗法的广泛潜力，并使公司能够潜在地深刻影响受影响患者的生活。”。

Dr. Hajjar’s addition to the Board is part of the planned Board refreshment process at Longeveron, with a focus on bringing in new, relevant, experienced leaders over time to add to the knowledge base and experience provided by current and departing Board members.

哈贾尔博士加入董事会是Longeveron董事会计划进修过程的一部分，重点是随着时间的推移引入新的、相关的、经验丰富的领导者，以增加现任和离职董事会成员提供的知识库和经验。

Dr. Hajjar is an internationally renowned scientific leader in the field of cardiac gene therapy. His laboratory had validated a number of cardiac targets that led to the initiation and completion under his guidance of First-in-Human gene therapy trials in patients with heart failure. He has initiated multiple clinical trials in gene therapy for a variety of cardiovascular diseases..

哈贾尔博士是心脏基因治疗领域国际知名的科学领导者。他的实验室已经验证了许多心脏靶点，这些靶点导致在他指导下对心力衰竭患者进行的首次人类基因治疗试验的启动和完成。他在多种心血管疾病的基因治疗方面启动了多项临床试验。。

He has authored over 500 publications and has received numerous awards for his achievements in the field of cardiac gene therapy. Dr. Hajjar received his Bachelor of Science in Biomedical Engineering from Johns Hopkins University and his Doctor of Medicine from Harvard Medical School and the Harvard-MIT Division of Health Sciences & Technology.

他撰写了500多篇出版物，并因其在心脏基因治疗领域的成就而获得了众多奖项。哈贾尔博士获得了约翰·霍普金斯大学生物医学工程理学学士学位，以及哈佛医学院和哈佛麻省理工学院健康科学与技术部的医学博士学位。

He completed his training in internal medicine, cardiology, heart failure/cardiac transplantation, and research fellowships at Massachusetts General Hospital in Boston where he then directed the Cardiology Laboratory of Integrative Physiology and Imaging. From 2007 to 2018, Dr. Hajjar was the Director of the Cardiovascular Research Center, and the Arthur & Janet C.

他在波士顿马萨诸塞州总医院完成了内科、心脏病学、心力衰竭/心脏移植和研究奖学金的培训，然后指导了综合生理学和影像学心脏病学实验室。从2007年到2018年，Hajjar博士担任心血管研究中心主任，Arthur＆Janet C。

Ross Professor of Medicine at Mount Sinai School of Medicine in New York. From 2019 to 2022, Dr. Hajjar was involved in the creation of a number of gene therapy companies at Flagship Pioneering, Cambridge, MA and he was the head of R&D at Ring Therapeutics..

纽约西奈山医学院（Mount Sinai School of Medicine）的罗斯（Ross）医学教授。2019年至2022年，哈贾尔（Hajjar）博士参与了马萨诸塞州剑桥市旗舰创业公司（Flagship Experianting）基因治疗公司的创建，并担任Ring Therapeutics的研发负责人。。

About Longeveron Inc.

关于Longeveron Inc。

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

Longeveron是一家临床阶段的生物技术公司，开发再生药物以满足未满足的医疗需求。该公司的主要研究产品是Lomecel-B™，一种从年轻健康成人供体的骨髓中分离出来的同种异体药物信号细胞（MSC）治疗产品。Lomecel-B™具有多种潜在的作用机制，包括促血管，促再生，抗炎以及组织修复和愈合作用，在一系列疾病领域具有广泛的潜在应用。

Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. The Lomecel-B™ HLHS program has received three distinct and important FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation.

Longeveron目前正在寻求三种管道适应症：发育不良的左心综合征（HLHS），阿尔茨海默病和衰老相关的虚弱。Lomecel-B™HLHS计划已获得三个不同且重要的FDA指定：孤儿药指定，快速通道指定和罕见儿科疾病指定。

For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram..

有关更多信息，请访问www.longeveron.com或在LinkedIn、X和Instagram上关注longeveron。。

Investor Contact:

投资者联系人：

Derek Cole

德里克·科尔

Investor Relations Advisory Solutions

投资者关系咨询解决方案

derek.cole@iradvisory.com

derek.cole@iradvisory.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ff5c44e-e63d-4909-b8b8-6d71186087ec

有关此公告的照片，请访问https://www.globenewswire.com/NewsRoom/AttachmentNg/0ff5c44e-e63d-4909-b8b8-6d71186087ec

Dr. Hajjar

Hajjar博士

Dr. Roger Hajjar, Director of the Gene and Cell Therapy Institute at Mass General Brigham

马萨诸塞州布莱根将军基因与细胞治疗研究所所长罗杰·哈贾尔博士